DelveInsight’s, “Major Depressive Disorder Pipeline Insight 2023” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Major Depressive Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Major Depressive Disorder Pipeline Report
- DelveInsight’s Major Depressive Disorder pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Major Depressive Disorder treatment.
- The leading companies working in the Major Depressive Disorder market include GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals, and others.
- Promising Major Depressive Disorder Pipeline Therapies in the various stages of development include Brexpiprazole, Cariprazine, Antidepressant Therapy (ADT), TC-5214, Brexpiprazole, BTRX-335140, and others.
- On April 2023, BlackThorn Theraeutics Inc. announced a study of Phase 2 Clinical Trials for BTRX-335140. A proof of concept (POC) study evaluating the impact of BTRX-335140 (NMRA-335140) relative to placebo on symptoms of major depressive disorder (MDD) in adult participants with MDD and symptoms of anhedonia and anxiety following 8 weeks of double-blind treatment as assessed by the HAMD-17 Scale.
- On September 2023, Otsuka Pharmaceutical Development & Commercialization Inc. announced a study of Phase 2 & 3 Clinical Trials for SEP-363856. This is a Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Flexible Doses of SEP-363856 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder (MDD).
Request a sample and discover the recent advances in Major Depressive Disorder Treatment Drugs @ Major Depressive Disorder Pipeline Report
The Major Depressive Disorder pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Major Depressive Disorder drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Major Depressive Disorder clinical trial landscape.
Major Depressive Disorder Overview
Major Depressive Disorder (MDD), also referred to as clinical depression, is a significant medical condition that can affect many areas of your life. It impacts mood and behavior as well as various physical functions, such as appetite and sleep.
Find out more about Major Depressive Disorder Treatment Drugs @ Drugs for Major Depressive Disorder Treatment
Major Depressive Disorder Emerging Drugs Profile
- SAGE-217: Sage Therapeutics
- REL-1017: Relmada Therapeutics, Inc
- Seltorexant: Minerva Sciences
- SP-624: Sirtsei Pharmaceuticals, Inc.
- SPL026: Small Pharma
- PDC-1421: BioLite Inc
Major Depressive Disorder Pipeline Therapeutics Assessment
The Major Depressive Disorder pipeline report proffers an integral view of the Major Depressive Disorder emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Learn more about the emerging Major Depressive Disorder Pipeline Therapies @ Major Depressive Disorder Clinical Trials Assessment
Scope of the Major Depressive Disorder Pipeline Report
- Coverage- Global
- Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Major Depressive Disorder Companies- GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals, and others.
- Major Depressive Disorder Pipeline Therapies- Brexpiprazole, Cariprazine, Antidepressant Therapy (ADT), TC-5214, Brexpiprazole, BTRX-335140, and others.
Dive deep into rich insights for new drugs for Major Depressive Disorder Treatment, Visit @ Major Depressive Disorder Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Major Depressive Disorder: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Major Depressive Disorder – DelveInsight’s Analytical Perspective
- Late Stage Products (Preregistration)
- SAGE-217: Sage Therapeutics
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- SP-624: Sirtsei Pharmaceuticals, Inc.
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- SPL026: Small Pharma
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Drug Name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Major Depressive Disorder Key Companies
- Major Depressive Disorder Key Products
- Major Depressive Disorder- Unmet Needs
- Major Depressive Disorder- Market Drivers and Barriers
- Major Depressive Disorder- Future Perspectives and Conclusion
- Major Depressive Disorder Analyst Views
- Major Depressive Disorder Key Companies
- Appendix
For further information on the Major Depressive Disorder Pipeline therapeutics, reach out to Major Depressive Disorder Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting